Company Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 02:27:53 2024-04-29 pm EDT			5-day change	1st Jan Change
0.175 ^CAD	0.00%		-2.78%	+20.69%

Apr. 03	Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	CI
Apr. 03	Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding	CI

Awakn Life Sciences Corp. is a Canada-based biotechnology company. The Company is engaged in the research, development, and commercializing of therapeutics to treat addiction with a focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company operates through three segments: development, delivery and corporate. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe. The Company operates in the United Kingdom (UK), Ireland and Canada.

Number of employees: 44

CAD in Million	2022	Weight	2023	Weight	Delta
Delivery (Services) 100.0 %	0	100.0 %	1	100.0 %	+533.52%

CAD in Million	2022	Weight	2023	Weight	Delta
Europe 100.0 %	0	100.0 %	1	100.0 %	+533.52%

Managers	Title	Age	Since
Anthony Tennyson FOU	Founder	-	-
Jonathan Held FOU	Founder	38	20-03-31
Shaun McNulty CTO	Chief Tech/Sci/R&D Officer	-	-
James Collins COO	Chief Operating Officer	-	-
David Nutt CTO	Chief Tech/Sci/R&D Officer	-	-
Arun Dhandayudham CTO	Chief Tech/Sci/R&D Officer	-	22-05-16
Gordo Whittaker IRO	Public Communications Contact	-	-
Naomi Junghae HRO	Human Resources Officer	-	-

Members of the board	Title	Age	Since
Paul Carter BRD	Director/Board Member	63	21-12-13
Stephen Page BRD	Director/Board Member	-	-
George Scorsis FOU	Founder	-	-
Anthony Tennyson FOU	Founder	-	-
John Papastergiou BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	38,591,197	35,330,516 ( 91.55 %)	0	91.55 %

Name	Equities	%	Valuation
Anthony Tennyson 5.241 %	2,022,706	5.241 %	182 044 $
George Scorsis 2.930 %	1,130,725	2.930 %	101 765 $
Jonathan Held 2.369 %	914,154	2.369 %	82 274 $
David Nutt 0.3634 %	140,250	0.3634 %	12 623 $
Stephen Page 0.1762 %	68,000	0.1762 %	6 120 $
John Papastergiou 0.1017 %	39,250	0.1017 %	3 533 $
Paul Carter 0.000000 %	0	0.000000 %	- $

Awakn Life Sciences Corp.

217 Queen Street West Suite 301

M5V 0R2, Toronto

http://www.awaknlifesciences.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
AWAKN LIFE SCIENCES CORP.	+20.69%	5.07M
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+47.70%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research